ACTS Member Feature
ACTS Welcomes New President: Emma A. Meagher, MD
ACTS is pleased to welcome Dr. Emma Meagher into the position of President. Currently, Dr. Meagher serves the University of Pennsylvania, Perelman School of Medicine as Vice Dean, Clinical Research & Chief Clinical Research Officer.
Dr. Meagher's educational interests are in the fields of translational research methodology to graduate, pre- and post-doctoral students and novel modalities for education in pharmacology to undergraduate medical (UME) students. To this end she directs the University of Pennsylvania pharmacology curriculum, is Program Director for the MTR and Co PI of the UPenn Clinical and Translational Sciences Award (CTSA).
Dr. Meagher's research interests have focused on the development of novel therapeutics in dyslipidemia. Her clinical practice focused on cardiovascular risk modification with an emphasis on management of dyslipidemia, hypertension and women's cardiovascular health.
Dr. Meagher has published articles in numerous journals, including Nature Medicine, the Journal of Clinical Investigation, JAMA, The Journal of Biological Chemistry, The American Journal of Cardiology, Hypertension and the Journal of Cardiovascular Pharmacology. She has written numerous reviews and book chapters, and has lectured widely at medical meetings, both nationally and internationally.
ACTS would like to extend its sincere gratitude to our outgoing President, Dr. Harry Selker, for his leadership and dedication to the Association.
Robert P. Kimberly, MD, Accepts New Role as ACTS President-Elect
Dr. Kimberly currently serves as Director, UAB Center for Clinical and Translational Science.
He is an internationally recognized translational scientist with substantial experience in the development and administration of large, multi-site and multiple-investigator scientific programs. His research group is interested in the role of genetic factors in the normal function of the immune system and in the development of autoimmune and immune-mediated inflammatory diseases such as systemic lupus erythematosus (SLE) and systemic vasculitis.
The team has been a leader in developing several national and international research consortia for the study of human diseases, and they have demonstrated that certain low-binding alleles are enriched in SLE patients.
Join us in welcoming Dr. Kimberly in his new role!